New Zealand - English - Ministry for Primary Industries

grosafe chemicals limited - etoxazole - etoxazole 110 g/litre - miticide

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer - etofamide - syrup - 20 mg/ml

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - indinavir sulphate eqv indinavir - capsule - 200 mg - indinavir sulphate eqv indinavir 200 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - telaprevir -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - boceprevir -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 250mg equivalent to 200 mg indinavir;  ;   - capsule - 200 mg - active: indinavir sulfate 250mg equivalent to 200 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint blue sb-6018 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 416.3mg equivalent to 333 mg indinavir;  ;   - capsule - 333 mg - active: indinavir sulfate 416.3mg equivalent to 333 mg indinavir     excipient: gelatin lactose magnesium stearate

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - indinavir sulfate 500mg equivalent to 400 mg indinavir;  ;   - capsule - 400 mg - active: indinavir sulfate 500mg equivalent to 400 mg indinavir     excipient: gelatin lactose magnesium stearate tekprint green sb-4020 - indicated for the treatment of adults with hiv-1 infection. clinical studies demonstrated: · reduced risk of progression to an aids-defining illness or death · increased overall survival · durable reduction in serum viral rna · durable increase in cd4 cell counts

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - telaprevir 375mg;   - film coated tablet - 375 mg - active: telaprevir 375mg   excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium hypromellose acetate succinate iron oxide yellow macrogol 3350 microcrystalline cellulose polyvinyl alcohol purified talc sodium laurilsulfate sodium stearyl fumarate titanium dioxide - incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis c in adult patients with compensated liver disease (including cirrhosis): - who are treatment naive - who have previously been treated with interferon alfa (pegylated or nonpegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - boceprevir 200mg - capsule - 200 mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 - victrelis (boceprevir) is indicated for the treatment of chronic hepatitis c (hcv) genotype 1 infection, in a combination regimen with peginterferon alpha and ribavirin, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.